Search

Your search keyword '"Pellarin, Ilenia"' showing total 3 results
Start Over Author "Pellarin, Ilenia" Topic dna repair
3 results on '"Pellarin, Ilenia"'

1. The Architectural Chromatin Factor High Mobility Group A1 Enhances DNA Ligase IV Activity Influencing DNA Repair.

Author

Pellarin I, Arnoldo L, Costantini S, Pegoraro S, Ros G, Penzo C, Triolo G, Demarchi F, Sgarra R, Vindigni A, and Manfioletti G

Subjects
Cell Line, Tumor, Chromatin metabolism, Chromatography, High Pressure Liquid, Comet Assay, HMGA1a Protein genetics, HMGA2 Protein genetics, HMGA2 Protein metabolism, Histones metabolism, Humans, Ku Autoantigen metabolism, MCF-7 Cells, Microscopy, Fluorescence, Phosphorylation, Recombinant Proteins biosynthesis, Recombinant Proteins chemistry, Recombinant Proteins isolation & purification, Substrate Specificity, Chromatin chemistry, DNA Ligase ATP metabolism, DNA Repair, HMGA1a Protein metabolism
Abstract

The HMGA1 architectural transcription factor is an oncogene overexpressed in the vast majority of human cancers. HMGA1 is a highly connected node in the nuclear molecular network and the key aspect of HMGA1 involvement in cancer development is that HMGA1 simultaneously confers cells multiple oncogenic hits, ranging from global chromatin structural and gene expression modifications up to the direct functional alterations of key cellular proteins. Interestingly, HMGA1 also modulates DNA damage repair pathways. In this work, we provide evidences linking HMGA1 with Non-Homologous End Joining DNA repair. We show that HMGA1 is in complex with and is a substrate for DNA-PK. HMGA1 enhances Ligase IV activity and it counteracts the repressive histone H1 activity towards DNA ends ligation. Moreover, breast cancer cells overexpressing HMGA1 show a faster recovery upon induction of DNA double-strand breaks, which is associated with a higher survival. These data suggest that resistance to DNA-damaging agents in cancer cells could be partially attributed to HMGA1 overexpression thus highlighting the relevance of considering HMGA1 expression levels in the selection of valuable and effective pharmacological regimens., Competing Interests: The authors have declared that no competing interests exist.

Published
2016
Full Text
View/download PDF

2. RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target.

Author

Pellarin, Ilenia, Belletti, Barbara, and Baldassarre, Gustavo

Subjects
RNA splicing, CANCER chemotherapy, OVARIAN cancer, BIOMARKERS, PLATINUM
Abstract

Since its discovery, alternative splicing has been recognized as a powerful way for a cell to amplify the genetic information and for a living organism to adapt, evolve, and survive. We now know that a very high number of genes are regulated by alternative splicing and that alterations of splicing have been observed in different types of human diseases, including cancer. Here, we review the accumulating knowledge that links the regulation of alternative splicing to the response to chemotherapy, focusing our attention on ovarian cancer and platinum‐based treatments. Moreover, we discuss how expanding information could be exploited to identify new possible biomarkers of platinum response, to better select patients, and/or to design new therapies able to overcome platinum resistance. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

3. The Architectural Chromatin Factor High Mobility Group A1 Enhances DNA Ligase IV Activity Influencing DNA Repair

Author

Francesca Demarchi, Guidalberto Manfioletti, Ilenia Pellarin, Riccardo Sgarra, Silvia Costantini, Laura Arnoldo, Alessandro Vindigni, Gloria Ros, Carlotta Penzo, Gianluca Triolo, Silvia Pegoraro, Pellarin, Ilenia, Arnoldo, Laura, Costantini, S, Pegoraro, Silvia, Ros, Gloria, Penzo, Carlotta, Triolo, G, Demarchi, F, Sgarra, Riccardo, Vindigni, A, and Manfioletti, Guidalberto

Subjects
0301 basic medicine, DNA Repair, lcsh:Medicine, Biochemistry, Substrate Specificity, Ligases, Histones, DNA Ligase ATP, 0302 clinical medicine, Cancer epigenetics, HMGA1a Protein, Post-Translational Modification, Phosphorylation, Ligation Assay, lcsh:Science, Chromatography, High Pressure Liquid, chemistry.chemical_classification, Multidisciplinary, biology, DNA repair protein XRCC4, Recombinant Proteins, Chromatin, Enzymes, Nucleic acids, Architectural transcription factors, 030220 oncology & carcinogenesis, MCF-7 Cells, DNA mismatch repair, Comet Assay, Research Article, DNA repair, Research and Analysis Methods, Non-Homologous End Joining, 03 medical and health sciences, breast cancer, Cell Line, Tumor, DNA-binding proteins, Genetics, Humans, Molecular Biology Techniques, Molecular Biology, Ku Autoantigen, DNA double-stranded breaks, Architectural transcription factors, DNA repair, DNA double-stranded breaks, breast cancer, DNA ligase, Molecular Biology Assays and Analysis Techniques, lcsh:R, HMGA2 Protein, Biology and Life Sciences, Proteins, DNA, Proliferating cell nuclear antigen, 030104 developmental biology, chemistry, Microscopy, Fluorescence, biology.protein, Cancer research, Enzymology, DNA damage, lcsh:Q, Nucleotide excision repair
Abstract

The HMGA1 architectural transcription factor is an oncogene overexpressed in the vast majority of human cancers. HMGA1 is a highly connected node in the nuclear molecular network and the key aspect of HMGA1 involvement in cancer development is that HMGA1 simultaneously confers cells multiple oncogenic hits, ranging from global chromatin structural and gene expression modifications up to the direct functional alterations of key cellular proteins. Interestingly, HMGA1 also modulates DNA damage repair pathways. In this work, we provide evidences linking HMGA1 with Non-Homologous End Joining DNA repair. We show that HMGA1 is in complex with and is a substrate for DNA-PK. HMGA1 enhances Ligase IV activity and it counteracts the repressive histone H1 activity towards DNA ends ligation. Moreover, breast cancer cells overexpressing HMGA1 show a faster recovery upon induction of DNA double-strand breaks, which is associated with a higher survival. These data suggest that resistance to DNA-damaging agents in cancer cells could be partially attributed to HMGA1 overexpression thus highlighting the relevance of considering HMGA1 expression levels in the selection of valuable and effective pharmacological regimens.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results